Understanding ROR1

ROR1, an oncogene recently discovered on chronic lymphocytic leukemia (CLL) B cells, is being studied by researchers as a potential target for CLL treatment. Dr. Brian Koffman met with Dr. Thomas Kipps, who is researching ROR1, at the 2014 American Society of Clinical Oncology (ASCO) meeting to discuss this oncogene and its potential use in treating CLL.

Click HERE: https://www.youtube.com/watch?v=Zji6Fux_WGo

Thanks to Patient Power!fig1

 

Hitting a CLL Treatment “Home Run”

As more chronic lymphocytic leukemia CLL treatments are approved, with many more in development, are researchers closer to hitting a “home run” in treating the disease? Patient advocate Dr. Brian Koffman met with CLL expert Dr. Thomas Kipps at ASCO 2014 to explore emerging therapies and the goal for patients to achieve deep remission.

Click here:  https://www.youtube.com/watch?v=CYS78SbXjKAHome run

Thanks to Patient Power!

Our New Newsletter is HOT off the Press!

We have our new newsletter is available!!  New news and articles letting you know the latest news in regards to CLL and the Blood Cancer Research Fund. Special thanks to Carolina Bump for her tireless efforts to get this information together!

Click here: Insight – BCRF Winter 2013 Newsletter 

Monoclonal Antibodies Could Add Power to CLL Treatment

Andrew Schorr from Patient Power in partnership with the CLL Global Research Foundation interview Dr. Thomas Kipps, Director of the Blood Cancer Research Fund and the CLL Research Consortium about the use of rituximab, a monoclonal antibody used to treat patients with chronic lymphocytic leukemia

Clink here to watch the video now!

Stopping the Spread of Cancer

Stopping cancer’s spread: New protein found to control deadly cancer metastasis

Researchers have found a critical element that may explain why some cancers spread farther and faster than others, a discovery that could lead to one of the Holy Grails of cancer treatment: containing the disease.

Scientists from the University of California, San Diego School of Medicine, Dr. Thomas J. Kipps and colleagues,  have identified a protein that seems to serve as a switch, regulating the spread of cancer from the primary tumor to distant spots in the body – a process known as metastasis.  The protein is used by embryo cells during early development, but then disappears from the body after an individual comes out of the womb.

Read more- Fox News Report: Dr. Kipps

ROR1 Antibody

Ibrutinib, a potential breakthrough in treating chronic lymphocytic leukemia (CLL)

(TIME.com) — It’s called ibrutinib, and it’s a potential breakthrough in treating chronic lymphocytic leukemia (CLL) that could leave patients with fewer side effects than chemotherapy.   

 

Read the story from CNN:  Ibrutinib new hope for CLL Treatment

 

Power of Positive Thinking

Stay Positive!  Several questions about the power of a positive outlook have come into us here at the BCRF.  While we are not psychologist there are volumes of information and research into the importance of positive attitudes!  Click on the links below for just some of the information that is out there:

“The day is what you make it! So why not make it a great one?” ~ Steve Schulte

Can you make the train go in either direction? Try it! It is possible to make it go away and towards you!

You’re Going Down CLL!!!

New pieces to the puzzle are being identified in the Kipps’ BCRF lab:

(click to see article links)

UCSD-led team finds leukemia-killing molecule

Dr. Thomas Kipps and researchers at the UC San Diego Moores Cancer Center have found a monoclonal antibody named RG7356 that may be effective in in killing chronic lymphocytic leukemia cells without harming healthy cells.

Read about it HERE

Embryonic Development Protein Active in Cancer Growth

Silencing it impairs tumor growth, making ROR1 a potential therapeutic target

A team of scientists at the University of California, San Diego Moores Cancer Center has identified a novel protein expressed by breast cancer cells – but not normal adult tissues – that could provide a new target for future anti-cancer drugs and treatments… Read the full story from the UCSD Newsroom

Read the study report in PLoS One

Study senior investigator Thomas J. Kipps, MD, PhD, is Evelyn and Edwin Tasch Chair in Cancer Research and professor of medicine in the Division of Hematology-Oncology. He is Interim Director of the UC San Diego Moores Cancer Center, where he co-leads the Hematologic Malignancies Program.

Dr. Kipps is principal investigator of the UC San Diego site in the Cancer Immunotherapy Trials Network, a research network established last year by the National Cancer Institute and headquartered at the Fred Hutchinson Cancer Research Center in Seattle.

Dr. Kipps was named to the National “Top Doctors” List for 2011-2012. In both 2010 and 2011, he was selected for the “San Diego Top Doctors” list.